News

https://www.wtnh.com/news/health/coronavirus/new-haven-biotech-receives-5m-from-bill-melinda-gates-foundation-for-covid-19-treatment/ … [Read more...] about New Haven biotech receives $5M from Bill & Melinda Gates Foundation for Covid-19 treatment | WTNH.com

The Grant from the Bill & Melinda Gates Foundation Accelerates Company’s Efforts to Enter Clinical Trials by Early 2021 NEW HAVEN, Conn., July 08, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, a … [Read more...] about Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients

Natural Killer (NK) Cells: Pushing the Next Wave of Immuno-Oncology Therapies https://lnkd.in/dFmQQj6 Password: 5J#j3@B+ … [Read more...] about BIO International Convention 2020 Virtual Recording Session featuring CEO Doug Manion

Getting to the Tumor: Beyond the First Generation of Tumor Targeting Technologies In oncology, going beyond the current standard of care will require increasingly potent therapies - drugs that must … [Read more...] about BIO INTERNATIONAL CONVENTION – DIGITAL ON DEMAND PANEL DISCUSSION – June 8th-June12th

NEW HAVEN, Conn., June 01, 2020 (GLOBE NEWSWIRE) -- Kleo Pharmaceuticals, Inc., a leading company in the field of developing next-generation, fully synthetic bispecific compounds designed to emulate … [Read more...] about Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference

Synergistic Potential of Kleo’s Antibody Recruiting Molecule (ARM™) and Celularity’s Placental-Derived NK Cells to Be Evaluated in the Context of COVID-19 and Multiple Myeloma New Haven, CT, … [Read more...] about Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma